Common Strategy for Adult and Pediatric Medulloblastoma: A Multicenter Series of 253 Adults
- Department of Radiation Oncology, Hopital de la Timone, Marseille (France)
- Department of Radiation Oncology, Centre Leon Berard, Lyon (France)
- Department of Biostatistics, Centre Leon Berard, Lyon (France)
- Department of Medical Oncology, Hopital de la Timone, Marseille (France)
- Department of Radiation Oncology, Institut Curie, Paris (France)
- Department of Radiation Oncology, Institut Gustave Roussy, Villejuif (France)
- Department of Radiation Oncology, Centre Alexis Vautrin, Nancy (France)
- Department of Radiation Oncology, Centre Val D'aurelle, Montpellier (France)
- Department of Radiation Oncology, Clinique de l'Orangerie, Strasbourg (France)
- Department of Radiation Oncology, Hopital Henry Mondor, Creteil (France)
- Department of Radiation Oncology, Hopital Saint Andre, Bordeaux (France)
Purpose: To assess prognostic factors for adults with medulloblastoma in a multicenter, retrospective study. Methods and Materials: Data were collected by file review or mail inquiry for 253 adults treated between 1975 to 2004. Radiologists or surgeons assessed disease characteristics, such as volume and extension. Patients were classified as having either high- or standard-risk disease. Prognostic factors were analyzed. Results: Median patient age was 29 years. Median follow-up was 7 years. Radiotherapy was delivered in 246 patients and radiochemotherapy in 142. Seventy-four patients relapsed. Respective 5- and 10-year overall survival rates were 72% and 55%. Univariate analysis showed that survival significantly correlated with metastasis, postsurgical performance status, brainstem involvement, involvement of the floor of the fourth ventricle (V4), and radiation dose to the spine and to the posterior cerebral fossa (PCF). By multivariate analysis, brainstem, V4 involvement, and dose to the PCF were negative prognostic factors. In the standard-risk subgroup there was no overall survival difference between patients treated with axial doses of {>=}34 Gy and patients treated with craniospinal doses <34 Gy plus chemotherapy. Conclusion: We report the largest series of medulloblastoma in adults. Prognostic factors were similar to those observed in children. Results suggest that patients with standard-risk disease could be treated with radiochemotherapy, reducing doses to the craniospinal area, maintaining at least 50 Gy to the PCF. The role of chemotherapy for this group is still unclear. A randomized study should be performed to confirm these results, but because frequency is very low, such a study would be difficult.
- OSTI ID:
- 20951662
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 68, Issue 2; Other Information: DOI: 10.1016/j.ijrobp.2006.12.030; PII: S0360-3016(06)03639-X; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Incidence, Risks, and Sequelae of Posterior Fossa Syndrome in Pediatric Medulloblastoma
Clinical Outcomes Among Children With Standard-Risk Medulloblastoma Treated With Proton and Photon Radiation Therapy: A Comparison of Disease Control and Overall Survival